Company intelligence / Profile preview

Trillium Group

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Trillium Therapeutics is a clinical-stage immuno-oncology company that was acquired by Pfizer in 2021 for approximately $2.26 billion. The company specializes in developing innovative therapies that target the CD47-SIRPα axis, a critical immune checkpoint used by cancer cells to evade the innate immune system. Its lead clinical candidates, TTI-621 and TTI-622, are SIRPα-Fc fusion proteins designed to block the "don't eat me" signal on cancer cells, thereby enhancing their destruction by macrophages. These assets are currently being integrated into Pfizer's broader oncology portfolio to address various hematologic malignancies and solid tumors.

Therapeutic areas: OncologyHematology
Modalities: Recombinant fusion proteinProtein
Industry: Biotech

Beyond the preview

Go deeper on Trillium Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trillium Group.

Explore the full profile